Related Experiment Videos
Targeting farnesyltransferase: is Ras relevant?
George C. Prendergast1, Wei Du
1The Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA
Abstract:
Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics that were developed to block the localization and thereby the activity of oncogenic Ras protein. Preclinical studies have established that FTIs are nontoxic yet capable of reversing malignant phenotypes. However, there is growing evidence that inhibition of Ras may not be crucial and that the antitransforming properties of FTIs are based at least in part upon alteration of Rho, a small GTPase which is involved in cell adhesion and cytoskeletal regulation. These recent developments are reviewed and their impact on the design of clinical trials is discussed. Copyright 1999 Harcourt Publishers Ltd.
Insights
Farnesyltransferase inhibitors (FTIs) show promise as cancer therapeutics by altering Rho GTPase activity, potentially reversing malignant phenotypes. This suggests a new therapeutic strategy beyond targeting Ras protein.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Farnesyltransferase inhibitors (FTIs) were developed as cancer therapeutics targeting the oncogenic Ras protein.
- Preclinical studies show FTIs are non-toxic and can reverse malignant phenotypes.
- Emerging evidence suggests FTIs' anti-transforming effects may involve Rho GTPase, not solely Ras.
Purpose of the Study:
- To review recent developments in FTI research.
- To discuss the role of Rho GTPase in FTI efficacy.
- To explore the impact of these findings on clinical trial design.
Main Methods:
- Literature review of preclinical and clinical studies on Farnesyltransferase inhibitors.
- Analysis of molecular mechanisms underlying FTI action, focusing on Ras and Rho GTPases.
- Discussion of implications for cancer therapeutic strategies and clinical trial design.
Main Results:
- FTIs exhibit anti-cancer properties through mechanisms potentially independent of Ras inhibition.
- Alteration of Rho GTPase activity is implicated in the antitransforming effects of FTIs.
- These findings necessitate a re-evaluation of FTI mechanisms and clinical trial strategies.
Conclusions:
- The therapeutic mechanisms of FTIs may extend beyond Ras inhibition to include modulation of Rho GTPase.
- Understanding the role of Rho is critical for optimizing FTI-based cancer therapies.
- Future clinical trials should consider Rho-related pathways in their design and evaluation of FTIs.